1,505
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Evaluation of the effect of etamsylate on thromboelastographic traces of canine blood with and without the addition of heparin

ORCID Icon, ORCID Icon, ORCID Icon & ORCID Icon
Pages 1-6 | Received 23 Feb 2023, Accepted 12 Sep 2023, Published online: 16 Sep 2023

References

  • Alvarez-Guerra M, Hernandez MR, Escolar G, Chiavaroli C, Garay RP, Hannaert P. 2002. The hemostatic agent ethamsylate enhances P-selectin membrane expression in human platelets and cultured endothelial cells. Thromb Res. 107(6):329–335. doi: 10.1016/s0049-3848(02)00353-5.
  • André P. 2004. P-selectin in haemostasis. Br J Haematol. 126(3):298–306. doi: 10.1111/j.1365-2141.2004.05032.x.
  • Angulo J, Peiró C, Romacho T, Fernández A, Cuevas B, González-Corrochano R, Giménez-Gallego G, de Tejada IS, Sánchez-Ferrer CF, Cuevas P, et al. 2011. Inhibition of vascular endothelial growth factor (VEGF)-induced endothelial proliferation, arterial relaxation, vascular permeability and angiogenesis by dobesilate. Eur J Pharmacol. 667(1-3):153–159. doi: 10.1016/j.ejphar.2011.06.015.
  • Bofill Rodriguez M, et al. 2022. Interventions for heavy menstrual bleeding; overview of Cochrane reviews and network meta-analysis. Cochrane Database Syst Rev. 5:CD013180.
  • Carter RLR, Talbot K, Hur WS, Meixner SC, Van Der Gugten JG, Holmes DT, Côté HCF, Kastrup CJ, Smith TW, Lee AYY, et al. 2018. Rivaroxaban and apixaban induce clotting factor Xa fibrinolytic activity. J Thromb Haemost. 16(11):2276–2288. doi: 10.1111/jth.14281.
  • Christopherson PW, Spangler EA, Boudreaux MK. 2012. Evaluation and clinical application of platelet function testing in small animal practice. Vet Clin North Am Small Anim Pract. 42(1):173–188. doi: 10.1016/j.cvsm.2011.09.013.
  • Cobo-Nuñez MY, El Assar M, Cuevas P, Sánchez-Ferrer A, Martínez-González J, Rodríguez-Mañas L, Angulo J. 2018. Haemostatic agent etamsylate in vitro and in vivo antagonizes anti-coagulant activity of heparin. Eur J Pharmacol. 827:167–172. doi: 10.1016/j.ejphar.2018.03.028.
  • Diquélou A, Barbaste C, Gabaig AM, Trumel C, Abella-Bourges N, Guelfi J-F, Bousquet Mélou A. 2005. Pharmacokinetics and pharmacodynamics of a therapeutic dose of unfractionated heparin (200 U/kg) administered subcutaneously or intravenously to healthy dogs. Vet Clin Pathol. 34(3):237–242. doi: 10.1111/j.1939-165x.2005.tb00047.x.
  • El Baser IIA, ElBendary HM, ElDerie A. 2021. The synergistic effect of tranexamic acid and ethamsylate combination on blood loss in pediatric cardiac surgery. Ann Card Anaesth. 24(1):17–23. doi: 10.4103/aca.ACA_84_19.
  • Flatland B, Koenigshof AM, Rozanski EA, Goggs R, Wiinberg B. 2014. Systematic evaluation of evidence on veterinary viscoelastic testing part 2: sample acquisition and handling. J Vet Emerg Crit Care. 24(1):30–36. doi: 10.1111/vec.12142.
  • Fletcher DJ, Blackstock KJ, Epstein K, Brainard BM. 2014. Evaluation of tranexamic acid and ε-aminocaproic acid concentrations required to inhibit fibrinolysis in plasma of dogs and humans. Am J Vet Res. 75(8):731–738. doi: 10.2460/ajvr.75.8.731.
  • Fraile L, Arcas A, Jiménez LM, Mallo J, Armengol R. 2019. Treatment with etamsylate reduces haemolactia in lactating dairy cows. J Dairy Res. 86(2):193–195. doi: 10.1017/S0022029919000219.
  • Fry W, Lester C, Etedali NM, Shaw S, DeLaforcade A, Webster CRL. 2017. Thromboelastography in dogs with chronic hepatopathies. J Vet Intern Med. 31(2):419–426. doi: 10.1111/jvim.14639.
  • Garay RP, Chiavaroli C, Hannaert P. 2006. Therapeutic efficacy and mechanism of action of ethamsylate, a long-standing hemostatic agent. Am J Ther. 13(3):236–247. doi: 10.1097/01.mjt.0000158336.62740.54.
  • Hecht P, Besser M, Falter F. 2020. Are we able to dose protamine accurately yet? A review of the protamine conundrum. J Extra Corpor Technol. 52(1):63–70. doi: 10.1051/ject/202052063.
  • Hernandez MR, Alvarez-Guerra M, Escolar G, Chiavaroli C, Hannaert P, Garay RP. 2004. The hemostatic agent ethamsylate promotes platelet/leukocyte aggregate formation in a model of vascular injury. Fundam Clin Pharmacol. 18(4):423–430. doi: 10.1111/j.1472-8206.2004.00256.x.
  • Homedes J. 2002. [El etamsilato como farmaco hemostatico en la clinica de bovino] [Doctoral dissertation, Universidad Atutonoma de Barcelona]. Etamsylate as hemostatic drug in bovines. http://hdl.handle.net/10803/5720.
  • Hunt R, Hey E. 2010. Ethamsylate for the prevention of morbidity and mortality in preterm or very low birth weight infants. Cochrane Database Syst Rev. CD004343(1): CD004343. doi: 10.1002/14651858.CD004343.pub2.
  • Hutton RA, Hales M, Kernoff PB. 1988. A study of the effect of ethamsylate (dicynene) on the bleeding time, von Willebrand factor level and fibrinolysis in patients with von Willebrand’s disease. Thromb Haemost. 60(3):506–507. doi: 10.1055/s-0038-1647000.
  • Kelley D, Lester C, Shaw S, de Laforcade A, Webster CRL. 2015. Thromboelastographic evaluation of dogs with acute liver disease. J Vet Intern Med. 29(4):1053–1062. doi: 10.1111/jvim.13441.
  • Majoy SB, de Laforcade AM, Barnard MR, Shaw SP. 2015. Platelet activation in a population of critically ill dogs as measured with whole blood flow cytometry and thromboelastography. Am J Vet Res. 76(4):328–337. doi: 10.2460/ajvr.76.4.328.
  • Marder VJ, Novokhatny V. 2010. Direct fibrinolytic agents: biochemical attributes, preclinical foundation and clinical potential. J Thromb Haemost. 8(3):433–444. doi: 10.1111/j.1538-7836.2009.03701.x.
  • McLaughlin CM, Marks SL, Dorman DC, Motsinger-Reif A, Hanel RM. 2017. Thromboelastographic monitoring of the effect of unfractionated heparin in healthy dogs. J Vet Emerg Crit Care. 27(1):71–81. doi: 10.1111/vec.12526.
  • McMichael MA, Smith SA. 2011. Viscoelastic coagulation testing: technology, applications, and limitations. Vet Clin Pathol. 40(2):140–153. doi: 10.1111/j.1939-165X.2011.00302.x.
  • Njau F, Shushakova N, Schenk H, Wulfmeyer VC, Bollin R, Menne J, Haller H. 2020. Calcium dobesilate reduces VEGF signaling by interfering with heparan sulfate binding site and protects from vascular complications in diabetic mice. PLoS One. 15(1):e0218494. doi: 10.1371/journal.pone.0218494.
  • Pittman JR, Koenig A, Brainard BM. 2010. The effect of unfractionated heparin on thrombelastographic analysis in healthy dogs. J Vet Emerg Crit Care. 20(2):216–223. doi: 10.1111/j.1476-4431.2010.00519.x.
  • R Core Team. 2021. R: A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing.
  • Segura D, Monreal L, Pérez-Pujol S, Alonso A, Díaz-Ricart M, Brugués R, Ordinas A, Escolar G. 2007. Effects of etamsylate on equine platelets: in vitro and in vivo studies. Vet J. 174(2):325–329. doi: 10.1016/j.tvjl.2006.06.002.
  • Spodsberg EH, Wiinberg B, Jessen LR, Marschner CB, Kristensen AT. 2013. Endogenous fibrinolytic potential in tissue-plasminogen activator-modified thromboelastography analysis is significantly decreased in dogs suffering from diseases predisposing to thrombosis. Vet Clin Pathol. 42(3):281–290. doi: 10.1111/vcp.12068.
  • Zmuda K, Neofotistos D, Ts’ao CH. 2000. Effects of unfractionated heparin, low-molecular-weight heparin, and heparinoid on thromboelastographic assay of blood coagulation. Am J Clin Pathol. 113(5):725–731. doi: 10.1309/Q4AE-BMCW-CQ7J-NUVT.